In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Aortic distensibility as assessed by CMR is independently associated with left ventricle function in patients with aortic valve regurgitation

Session Poster session 2

Speaker Rui Placido

Event : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance: Systolic and Diastolic Function
  • Session type : Poster Session

Authors : R Placido (Lisbon,PT), J Rigueira (Lisbon,PT), LB Rosario (Lisbon,PT), P Carrilho-Ferreira (Lisbon,PT), C David (Lisbon,PT), FJ Pinto (Lisbon,PT), AG Almeida (Lisbon,PT)

Authors:
R Placido1 , J Rigueira1 , LB Rosario1 , P Carrilho-Ferreira1 , C David1 , FJ Pinto1 , AG Almeida1 , 1Hospital Lisbon North, Hospital Santa Maria - Lisbon - Portugal ,

Citation:
European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii340

Previous works have found that aortic distensibility (AD) is a determinant factor on the pathophysiology of hypertension, coronary artery disease, aortic disease of Marfan, left ventricle failure. In this study we aimed to assess whether in patients with chronic aortic valve regurgitation (AR), AD had influence on left ventricle (LV) volumes and function, as assessed by CMR.

Methods: We studied 63 consecutive patients (aged 47±9 year-old; 54 men) with severe AR based on the presence of regurgitant fraction (RF) >33% as assessed by CMR. Coronary artery disease was excluded by coronary angiography or cardiac CT. Exclusion criteria: non-sinus rhythm, presence of other significant valve disease, coronary disease.

All patients were submitted to CMR (SSFP, phase contrast velocity coding) using a 3T scanner. LV feature tracking analysis was performed (Circle cvi42). Besides demographics and clinical data, the following variables were assessed: maximal dimension of the ascending aorta (mm); AD of the proximal ascending aorta, calculated as: (Variation between end-systolic and end-diastolic area (cm2)/end-diastolic area (cm2)) / pulse pressure (dynes cm-1; 1 mmHg=1,332 dynes cm-1); RF (%). LV end-diastolic volume (EDV) (mL), ejection fraction (%) and global longitudinal strain (GLS) (%) by feature tracking analysis, were endpoints as markers of LV function.

Results: Maximal diameter of the ascending aorta was 37±4 mm, AD was 0.63±0.80 dynes cm-1 (0.05-2.2), RF was 38±3.6%, EDV was 120±17 ml/m2, EF 62±8.1% and GLS 16±3.1%. There was no difference on LV volumes, ejection fraction according to gender, presence of symptoms or presence of risk factors, but GLS was lower in the group with symptoms. No correlation was found between blood pressure or maximal ascending aorta diameter and LV volumes, ejection fraction or GLS. We found a significant correlation between RF and EDV (r=0.040, p=0.02), an inverse correlation between age and GLS (r=-0.38, p=0.05), and between AD and LV EDV (r=-0.50, p=0.008), ejection fraction (r=-0.59, p=0.002) and GLS (r=-0.65, p=0.001). AD was an independent predictor of reduced GLS.

Conclusion: In patients with significant aortic regurgitation, aortic distensibility was independently associated with LV dysfunction. This may have prognostic and therapeutic implications, namely on the timing for surgical intervention.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are